Skip to content
All Podcasts – Lifestyle
Author:
Spyre Therapeutics, Inc.
Spyre Therapeutics Announces Grants of Inducement Awards
October 2, 2026
Spyre’s SPY003 Shows Positive Results in Ulcerative Colitis Trial
September 8, 2026
Spyre Therapeutics Announces Grants of Inducement Awards
September 4, 2026
Spyre Therapeutics to Participate in Upcoming September Investor Conferences
September 3, 2026
Spyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurativa
August 10, 2026
Spyre Therapeutics Announces Grants of Inducement Awards
August 7, 2026
Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 4, 2026
Spyre Therapeutics Announces Grants of Inducement Awards
July 2, 2026
Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
June 15, 2026
Spyre Therapeutics Announces Grants of Inducement Awards
June 5, 2026
1
2
Next Page
→